Company intelligence / Profile preview

Reach Neuro

Pittsburgh, Pennsylvania, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Reach Neuro’s Avantis spinal cord stimulation platform has been evaluated in an NIH-funded acute clinical study in 7 chronic stroke participants, showing immediate and lasting improvements in upper-limb motor control and reductions in spasticity, with some patients regaining functional abilities such as using utensils and manipulating objects; the system has received FDA Breakthrough Device designation and is moving toward longer-term at‑home and fully implanted trials.[2][3][5]

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

University of PittsburghCarnegie Mellon UniversityUniversity of Pittsburgh Medical Center (UPMC)National Institutes of Health (NIH) BRAIN InitiativeNEMIC (New England Medical Innovation Center)

Beyond the preview

Go deeper on Reach Neuro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reach Neuro.

Explore the full profile